April 16, 2025: Attorneys in Ozempic Lawsuit Argue Over Diagnostic Criteria for Gastroparesis Attorneys in the multidistrict litigation against Ozempic and other GLP-1 manufacturers are disagreeing about what constitutes a gastroparesis diagnosis
The FDA has received reports of patients erroneously injecting too much or healthcare providers calculating incorrect doses resulting in the need for medical attention or hospitalization
Thats unhelpful to weight management
When considering the science behind GLP-1s, this outcome aligns with expectations
The encapsulation efficiency of SEMA was 90.5 0.82% (Table 2)
PEG has considerable side effects, however, including nausea, flatulence, and diarrhea, particularly in older individuals (Leung, Riutta 2011